PCVX

VAXCYTE INC

Investor Moves

NameValueActionChangePriceLast Price
Steven CohenPoint72
$36M620.4k shares
AddQ1 2026
$29M
$58.11
$56.74
Ken GriffinCitadel Advisors
$11M197.6k shares
TrimQ1 2026
$7M
$58.11
$56.74
Jim SimonsRenaissance Technologies
$3M54.7k shares
AddQ1 2026
$172k
$58.11
$56.74
Steven CohenPoint72
$-17.6M
TrimQ4 2025
$18M
--
$56.74
Ken GriffinCitadel Advisors
$9.3M
AddQ4 2025
$9M
--
$56.74
Ray DalioBridgewater Associates
$-427.0K
ExitQ4 2025
$427k
--
$56.74

Congress Trades

NameValueActionAmount RangePriceLast Price
Gilbert CisnerosDemocrat
$8k
BuyMay 13, 2026
$1k-$15k
--
$56.74
Gilbert CisnerosDemocrat
$8k
BuyMay 12, 2026
$1k-$15k
--
$56.74

Insider Trades

NameValueActionPriceLast Price
Wassil JimCHIEF OPERATING OFFICER
$128k2.3k shares
SellMay 1, 2026
$56.83
$56.74
Cowan ElviaSVP, Finance & CAO
$180k3k shares
SellApr 7, 2026
$60.00
$56.74
Wassil JimCHIEF OPERATING OFFICER
$82k1.4k shares
SellApr 1, 2026
$58.14
$56.74
Wassil JimCHIEF OPERATING OFFICER
$49k838 shares
SellApr 1, 2026
$58.93
$56.74
Cowan ElviaSVP, Finance & CAO
$82k1.5k shares
SellMar 17, 2026
$55.39
$56.74
Cowan ElviaSVP, Finance & CAO
$23k405 shares
SellMar 17, 2026
$56.26
$56.74

News

globenewswire.comVaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adultsglobenewswire.comJun 2seekingalpha.comVaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.comMay 12globenewswire.comVaxcyte Reports First Quarter 2026 Financial Results and Provides Business Updateglobenewswire.comMay 6seekingalpha.comVaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Marketseekingalpha.comMay 1globenewswire.comVaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conferenceglobenewswire.comApr 7